A radioinhibitor binding assay and an enzyme inhibition assay have been developed to measure plasma levels of CGP 38 560, a potent human renin inhibitor. The detection limit of the assays was between 0.5 and 1 pmol/ml. There was a good correlation (r=0.989) between the two assays for the measurement of human plasma spiked with CGP 38 560 in concentrations from 1.9 nM to 12 fiM. Intra-assay variability was 6.1-17.3% and 4.4-27.2% for the radioinhibitor binding assay and the enzyme inhibition assay, respectively. Interassay variability was 6.0-28.2% and 3.8-28.4% for the radioinhibitor binding assay and the enzyme inhibition assay, respectively. Blood samples were collected during a pharmacological study performed in normotensive human volunteers on an unrestricted diet who were infused during a 30-minute period with T he renin-angiotensin system plays a major role in the regulation of blood pressure and in the maintenance of sodium and volume homeostasis. The enzymatic cleavage of angiotensinogen by human renin (EC 3.4.23.15) generates a decapeptide, angiotensin I, which is immediately hydrolyzed by a carboxydipeptidyl hydrolase, the angiotensin converting enzyme (EC 3.4.15.1), to the octapeptide angiotensin II, a potent vasoconstrictor. Renin has only one known substrate, angiotensinogen, and therefore provides an interesting target for the design of specific blockers of the renin-angiotensin system. During recent years, several specific and potent inhibitors of primate renin have been synthesized and characterized in vitro and in vivo. The in vitro studies have demonstrated the potency and specificity of the compounds against renin from different species and other aspartic proteinases, 1 and the in vivo studies have demonstrated the effects of renin inhibitors on blood
T he renin-angiotensin system plays a major role in the regulation of blood pressure and in the maintenance of sodium and volume homeostasis. The enzymatic cleavage of angiotensinogen by human renin (EC 3.4.23.15) generates a decapeptide, angiotensin I, which is immediately hydrolyzed by a carboxydipeptidyl hydrolase, the angiotensin converting enzyme (EC 3.4.15.1), to the octapeptide angiotensin II, a potent vasoconstrictor. Renin has only one known substrate, angiotensinogen, and therefore provides an interesting target for the design of specific blockers of the renin-angiotensin system. During recent years, several specific and potent inhibitors of primate renin have been synthesized and characterized in vitro and in vivo. The in vitro studies have demonstrated the potency and specificity of the compounds against renin from different species and other aspartic proteinases, 1 and the in vivo studies have demonstrated the effects of renin inhibitors on blood However, little is known about the pharmacokinetics of the inhibitors and the relation between the plasma concentration and the pharmacodynamic response. One reason has been the lack of analytical methods sensitive enough to measure the plasma concentration of the inhibitors in the biologically effective range (10~6 to 10" 9 mol/1). Some pharmacokinetic and metabolic experiments have been done with a radiolabeled inhibitor, 4 but assays that do not need radiolabeling are clearly an advantage. We therefore developed a radioinhibitor binding assay (RIBA) and an enzyme inhibition assay for the measurement of different renin inhibitors in biological fluids. Both assays are based on the recognition of the inhibitor by the active site of human renin. In the present study, these two methods were used to quantify plasma levels of CGP 38 560, a potent transition-state inhibitor of primate renin.
Materials and Methods
Human renin used in the RIBA was extracted from cadaver kidneys 5 and purified by immunoaffinity chromatography with R 3-36-16, a monoclonal antibody directed against human renin. 6 The specific activity of the purified enzyme was 150-200 Goldblatt units (GU)/mg protein. Renin used in the enzyme inhibition assay was obtained from Medical Research Council, Division of Biological Standards (Holly Hill, London, England) with a specific activity of 5.3 xlO" 3 GU/mg protein. Outdated plasma obtained from a local blood bank was used as a source of angiotensinogen without any pretreatment in the enzyme inhibition assay. The renin-free plasma used in the RIBA was obtained after passage of outdated plasma through an immunoaffinity column containing monoclonal antibodies against human renin (R 3-36-16). 6 CGP 38 560, AT-(2(5)-benzyl-3-ter-butylsulfonylpropy^His-Cha^al-n-butylamide*, was synthesized by Ciba-Geigy (Basel, Switzerland) ( Figure 1 ). CGP 38 560 A is the methane sulfonate salt of CGP 38 560. CGP 38 560 was radiolabeled with tritium at C-2 and C-4 (or C-5) positions of the imidazole ring of histidine. The stability of the label was tested under physiological conditions. 7 The C-4 and C-5 positions were totally resistant to aqueous exchange, and the rate of exchange was about 0.5% per hour at the C-2 position. [ 3 H]CGP 38 560 has a specific activity of 46.7 Ci/mmol (Ciba-Geigy, Horsham, UK). Thin-layer silica gel chromatography with CHCyO^OH/HjO/ CH3COOH (90/10/1/0.5) as eluent showed the radiolabeled inhibitor to be 97.8% pure.
The bovine serum albumin (BSA), 8-hydroxyquinoline sulfate, and Tween 20 (polyoxyethylenesorbitan monolaurate) were from Fluka (Buchs, Switzerland). Brij 35 (polyoxyethylene lauryl ether) and charcoal Norit A were obtained from Serva (Heidelberg, Germany). Irgascint A 300 was from Ciba-Geigy. All reagents were of the highest grade available.
The incubation buffer for RIBA (buffer A) consisted of 0.1 M Tris-acetate buffer, pH 5.7, containing 1% (wt/vol) Brij 35 and 1 mg/ml BSA. The incubation buffer for the enzyme inhibition assay (buffer B) consisted of 6.7 mM phosphate buffer, pH 5.7, containing 6 mM EDTA and 1.5 mM 8-hydroxyquinoline sulfate and Tween 20.
Radioinhibitor Binding Assay .
The assay is based on competition between unlabeled renin inhibitors and [ action, the amount of radiolabeled renin inhibitor complexes formed is inversely proportional to the quantity of unlabeled renin inhibitor present in the incubation mixture. A standard curve obtained from samples with known amounts of renin inhibitor was used to measure the inhibitor in unknown samples.
Preparation of standards. A stock solution of CGP 38 560 A (1 mg/ml) was prepared in H 2 O and stored at -20° C. It was diluted with human reninfree plasma to yield standards containing 0.46-60 pmol/ml.
Preparation of spiked samples. Ten spiked samples were prepared from human plasma by adding stock solution of CGP 38 560 A and serial dilutions with human renin-free plasma. They were used to determine stability in plasma and to compare the assay methods and the variations of both methods.
Assay procedure. Standards or unknown plasma samples (50 /A) were incubated with [ ]CGP 38 560 were separated using a slight modification of the previously described dextran-coated charcoal method. 8 Briefly, 200 fi\ of the charcoal suspension (1.25 g charcoal and 0.25 g dextran in 100 ml buffer A) was added, and after 5 minutes the mixture was centrifuged for 20 minutes at 3,000g. An aliquot of the supernatant (usually 200 /A) was pipetted into vials and counted in the liquid scintillation counter after addition of 10 ml Irgascint A 300.
Plasma samples containing more than 15 pmol/ml of CGP 38 560 were diluted with renin-free human plasma to a final concentration of 1-15 pmol/ml before analysis. The incubations were made in triplicate. 
Enzyme Inhibition Assay
The enzyme inhibition assay is a modification of the assay reported for benazeprilat. 9 Well-defined concentrations of human renin and angiotensinogen were incubated with plasma samples containing or not containing renin inhibitors, and the amount of angiotensin I generated was measured by radioimmunoassay. 10 Further degradation of angiotensin I was prevented with EDTA and 8-hydroxyquinoline sulfate. A standard curve obtained from plasma samples with known amounts of renin inhibitor was used to quantify CGP 38 560 in unknown plasma samples.
Preparation of standards and samples. CGP 38 560 was dissolved in 40% ethanol (0.577 mg/ml) and diluted with water to give a stock solution of 100 nmol/ml. Seven standards containing 0.07-50 pmol/ ml were prepared by adding stock solution to buffer and further diluting with renin-free plasma. Five plasma samples, spiked with CGP 38 560 to a final concentration of 0.24-1,000 pmol/ml, were prepared from another stock solution stored (-20° C) in aliquots. They were used as control with each assay. Plasma samples containing more than 10 pmol/ml of CGP 38 560 were diluted with renin-free plasma before analysis.
Incubation procedure. Fifty microliters standard or sample plasma was added to 100 \A renin-free plasma in polypropylene tubes (9x55 mm). After preincubation for 2 hours in a water bath at 37° C, 200 \A renin solution (0.5 pg protein///! buffer B) was added, and incubation was continued for another 6 hours in a shaking water bath. The reaction was stopped by placing the vials on dry ice and the samples were kept below -20° C until analysis by radioimmunoassay. 10 The incubations were made in duplicate.
Calculations. Angiotensin I, formed in the presence of the standard concentrations of CGP 38 560, was plotted against log of the concentration of CGP 38 560. A computer program with a cubic spline function and a smoothing factor 11 was used to visually fit a curve to the standard points. Concentrations of CGP 38 560 in controls and samples were calculated from this standard curve and expressed in equivalents of CGP 38 560.
Pharmacological study in normotensive human volunteers. Human volunteers on an unrestricted diet received a 30-minute infusion of CGP 38 560 A (50 jug/kg dissolved in glucose 5%) for the treated group (n=5) and vehicle (glucose 5%) for the placebo group (n=5). Blood pressure and heart rate were recorded during the experiment with a DINA-MAP automatic blood pressure recorder (Critikon Inc., Tampa, Florida). Blood samples were collected on EDTA before and 10, 20, 30, 40, 50, 60, and 180 minutes after the beginning of the infusion. Plasma was obtained by centrifugation. The plasma levels of equivalent CGP 38 560 were determined by the RIBA and enzyme inhibitor assay. Each plasma sample was measured in triplicate. Plasma renin activity was measured as the rate of angiotensin I generated after 2 hours of incubation (37° C) of the plasma at pH 7.2. Angiotensin I produced was measured by radioimmunoassay as previously described. 10 Active renin was quantitated with a radioimmunometric assay (Pasteur Production, Marnes-la-Coquette, France). 12 The data were statistically evaluated with Dunnett's test.
Results

Radioinhibitor Binding Assay
Standard curve. A standard curve for CGP 38 560 constructed from the means of the data points from seven individual standard curves is shown in Figure 2 . The mean IC 50 value was 5.34±1.22 pmol/ml, and the coefficient of variation, defined as the ratio of standard deviation to mean, was 22.8%. The limit of detection defined as Bo+2 SD, was 0.9 pmol/ml (0.65 ng/ml). The standard curve allowed the determination of concentrations of CGP 38 560 over a range of 0.9-15 pmol/ml. Samples with higher concentrations were diluted with blank plasma before assessment.
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CGP 38 560 A (pmol/ml) Intra-assay variability. Ten spiked plasma samples with CGP 38 560 were assayed five times in a single assay to determine the intra-assay variation (Table 1) . Recoveries were in the range of 72.1-102.5% with a coefficient of variation of 6.1-17.3%.
Interassay variability. The same 10 spiked samples were assayed in triplicate on five different days to determine the stability and the interassay variation (Table 1) . CGP 38 560 was stable in plasma over a period of several days. Recoveries were in the range of 74.6-100% with a coefficient of variation of 6.0-28.2%.
Enzyme Inhibition Assay
Standard curve. A representative standard curve obtained with plasma samples containing 0.07-50 pmol/ml CGP 38 560 is shown in Figure 3 . The limit of detection was determined with blank plasma from healthy individuals. The mean of equivalent CGP 38 560 concentration found was 0.183±0.14 pmol/ml (n=12). On the basis of these results, the limit of detection in human plasma was estimated to be 0.5 pmol/ml (mean ±2 SD). The standard curve could be used reliably over the range of 0.5-10 pmol/ml. Samples with higher concentrations of CGP 38 560 were diluted with blank plasma before analysis.
Intra-assay variability. Ten spiked plasma samples were assessed five times in duplicate in one assay to determine intra-assay variation (Table 2) . Recoveries were 60.3-114.7% with a coefficient of variation of 4.4-27.2%.
Interassay variability. Ten spiked plasma samples were analyzed in duplicate on five different days to determine the stability and the interassay variation (Table 2 ). CGP 38 560 was stable in plasma over a period of several days. Recoveries were 87-134.8% with a coefficient of variation of 3.8-28.4%.
Comparison of the Two Assays
Spiked plasma samples. Ten spiked plasma samples with CGP 38 560 were analyzed with the RIBA and the enzyme inhibition assay, and the results were compared. Figure 4 shows the data obtained with the RIBA (ordinate) versus the enzyme inhibition assay (abscissa). A linear least-squares regression analysis of the untransformed data yielded an equation y=0.982* and a correlation coefficient of 0.989 (n=10), indicating a good correlation between the two assays for spiked samples.
Pharmacological Study in Normotensive Human Volunteers
After intravenous infusion of CGP 38 560 A (50 jig/kg) in normotensive human volunteers on an unrestricted diet, blood pressure and heart rate were unchanged (Table 3) . Plasma concentrations of equivalent CGP 38 560 measured by RIBA and by the enzyme inhibitor assay were not significantly different (p>0.05), and there was a significant correlation between values obtained by the different methods (r=0.94) ( Figure 5A ). The plasma content of equivalent CGP 38 560 reached a maximum of 311±46.5 and 345.7+143.8 nM for the RIBA and the enzyme inhibitor assay, respectively (n=5, mean±SEM, /?>0.05) at the end of the infusion period (30 minutes). When the infusion was stopped, renin inhibitor plasma levels fell rapidly to 1.29±0.2 and 3.0±1.35 nM for the RIBA and the enzyme inhibitor assay, respectively (n=5, mean±SEM, /?>0.05) at time 180 minutes. Plasma renin activity was completely inhibited 10 minutes after the beginning of the infusion and remained inhibited over the observation period of 180 minutes ( Figure 5B ). Plasma concentrations of active renin increased by a factor of two ( Figure 5C ), reaching a maximum between 30 and 40 minutes after the beginning of the infusion. At the end of the infusion, active renin declined progressively to placebo values.
Discussion
During the last decade, numerous renin inhibitors have been synthesized and characterized in vitro Results are expressed as mean±SEM (n=5). MAP, arterial blood pressure; HR, heart rate. and in vivo. So far, no assays have been available to quantitate renin inhibitors in biological fluids. The elimination and metabolism of a renin inhibitor in the bile of dogs has been described previously. 13 The excreted compound was analyzed after protein precipitation and high-performance liquid chromatography. However, this method is not sensitive enough to measure the plasma levels of inhibitor in the range where they are effective (pmol/ml). The routes of elimination of a tritiated renin inhibitor have been studied after intravenous and intraduodenal administration. 4 Concentrations of radioactivity were measured in the urine, bile, plasma, and feces. One disadvantage of this approach is that it is not possible to distinguish between intact drug and metabolites (inactive or active) without a separation step. An additional limitation is that each different renin inhibitor to be studied has to be radiolabeled.
The present study describes two methods of quantifying levels of renin inhibitors in biological fluids. One major advantage of both methods is that they can be applied to any type of inhibitor, regardless of the chemical structure. Both methods were sensitive enough to detect inhibitors in concentrations of 0.5-1 nM, which correspond to the biologically active concentrations of most potent renin inhibitors. A good correlation was obtained after comparison of human plasma spiked with CGP 38 560. The RIBA takes less time to perform than the enzyme inhibition assay, and it involves only one step, so that there is less likelihood of interference. However, a similar variability was found with both methods.
The two methods gave comparable values for the plasma concentrations of equivalent CGP 38 560 in human volunteers. With both assays, plasma levels of the renin inhibitor reached a maximum at the end of the infusion and rapidly decreased when the infusion ended. The short plasma half-life may be due to a large first pass effect as has been reported in animal studies with other renin inhibitors. 4 - 13 The plasma concentrations of the renin inhibitor measured over the 180-minute observation period were in excess of the concentration required to inhibit renin activity by 50% in vitro (0.7 nM), which is consistent with the suppressed values of plasma renin activity. 14 The changes in plasma concentrations of active renin were opposite to the changes in plasma renin activity. The increase in active renin was probably a consequence of a reduction in the negative feedback of angiotensin II on renin secretion by the kidney. The time course in the changes in those biochemical parameters was in parallel with the changes in the concentrations of the renin inhibitor.
In summary, two assays for the measurement of plasma concentrations of biologically active inhibitors in humans have been described and evaluated. Although the two methods give similar results, the RIBA has the advantage of being faster and easier. Information obtained with such assays allows a deeper insight into the relations between the pharmacokinetic and the pharmacodynamic properties of renin inhibitors.
